Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride (KCl) provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse transmission, muscle contraction, and enzymatic reactions. Dextrose 5% provides glucose for energy, and sodium chloride 0.45% provides sodium and chloride ions for electrolyte balance and volume expansion.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
40 mEq potassium chloride intravenously at a rate not exceeding 10 mEq/hour; typically infused over 4-6 hours. Maximum 24-hour dose: 200 mEq.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal elimination half-life is approximately 3-5 minutes for rapid redistribution phase; effective half-life for total body potassium is 30-40 hours due to large intracellular pool. Clinical context: immediately after IV infusion, plasma potassium declines rapidly due to cellular uptake, but total elimination depends on renal function.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: >90% excreted unchanged by kidneys. Fecal: <10% via secretion into feces.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."